Standigm

Standigm, Inc. is a South Korean artificial-intelligence drug discovery company headquartered in Seoul (Gangnam-gu). It applies workflow AI across the early drug discovery process, from first-in-class target identification through lead generation and optimization to preclinical candidate stages. Its stated proprietary platforms include Standigm ASK for target discovery, Standigm BEST for lead design, Standigm Insight for drug repurposing, and DarkMolFactory for automated molecular design; AI SaaS and API products STELLA and SPICA are described for target identification and optimization tasks.

The company positions itself in the AI-enabled small-molecule discovery segment, with reported therapeutic activity in oncology, and describes reducing average material optimization time from roughly 4.5 years to about 1.5 years and producing first-in-class lead compounds within about seven months. Its website markets an early-access offer of 1,000 generated molecule ideas for a given target within one week, alongside a two-week free trial of its AI tools limited to a set number of participants.

Third-party profiles classify Standigm under pharmaceutical manufacturing and healthcare IT with sub-industries spanning bioinformatics, pharmaceutical R&D and medical software, and record a Series B company stage.